Neoadjuvant Durvalumab/Olaparib Active in Muscle-Invasive Bladder Cancer

Wayne Kuznar
Published: Saturday, Feb 15, 2020
Juan Francisco Rodriguez-Moreno, medical oncologist at HM Hospitales

Juan Francisco Rodriguez-Moreno

A neoadjuvant regimen of durvalumab (Imfinzi) plus olaparib (Lynparza) induced a pathologic complete response (pCR) rate of 50% in patients with muscle-invasive bladder carcinoma (MIBC), according to findings from the phase II NEODURVARIB trial.1

Pre- and post-treatment blood samples are being analyzed for PD-L1 expression and pattern of immune infiltration. Whole exome sequencing is being performed in all tumor samples.


  1. Rodriguez-Moreno JF, de Velasco G, Bravo Fernandez I, et al. Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial. Presented at: GU Cancers Symposium; February 13-15, 2020; San Francisco, CA. Abstract 542.
  2. Gao J, Siefker-Radtke AO, Navai N, et al. A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin- based neoadjuvant chemotherapy (NAC). J Clin Oncol. 2019;37 (suppl 15):4551.Abstr 4551. doi: 10.1200/JCO.2019.37.15_suppl.4551.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication